Index RUT P/E 9.49 EPS (ttm) 2.54 Insider Own 1.47% Shs Outstand 166.98M Perf Week -2.55%
Market Cap 4.07B Forward P/E 9.23 EPS next Y 2.61 Insider Trans -0.63% Shs Float 166.70M Perf Month -6.82%
Income 434.43M PEG 0.38 EPS next Q 0.67 Inst Own 104.65% Short Float 8.11% Perf Quarter -10.06%
Sales 1.73B P/S 2.36 EPS this Y 90.93% Inst Trans -1.26% Short Ratio 6.55 Perf Half Y 5.42%
Book/sh 7.42 P/B 3.24 EPS next Y -5.21% ROA 23.94% Short Interest 13.52M Perf Year -9.70%
Cash/sh 4.40 P/C 5.46 EPS next 5Y 24.80% ROE 42.85% 52W Range 20.46 - 32.88 Perf YTD -13.30%
Dividend Est. - P/FCF 10.32 EPS past 5Y - ROI 26.88% 52W High -26.86% Beta 0.49
Dividend TTM - Quick Ratio 2.77 Sales past 5Y 10.61% Gross Margin 83.32% 52W Low 17.54% ATR (14) 0.73
Dividend Ex-Date - Current Ratio 3.20 EPS Y/Y TTM 361.04% Oper. Margin 22.07% RSI (14) 37.77 Volatility 2.89% 2.96%
Employees 2100 Debt/Eq 0.29 Sales Y/Y TTM 54.01% Profit Margin 25.17% Recom 2.15 Target Price 34.25
Option/Short Yes / Yes LT Debt/Eq 0.29 EPS Q/Q 183.98% Payout 0.00% Rel Volume 0.65 Prev Close 23.86
Sales Surprise -2.74% EPS Surprise -26.21% Sales Q/Q 21.83% Earnings May 01 BMO Avg Volume 2.06M Price 24.05
SMA20 -2.46% SMA50 -10.50% SMA200 -9.51% Trades
Volume 1,347,148 Change 0.80%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-19-24 Initiated Robert W. Baird
Outperform
$37
Feb-20-24 Downgrade UBS
Neutral → Sell
$25
Nov-20-23 Resumed JP Morgan
Neutral
$33
Oct-24-23 Upgrade Evercore ISI
In-line → Outperform
Oct-17-23 Initiated UBS
Neutral
$31
Nov-03-22 Upgrade Piper Sandler
Neutral → Overweight
$26 → $30
Oct-14-22 Upgrade BofA Securities
Underperform → Neutral
$27 → $25
Aug-16-22 Initiated Piper Sandler
Neutral
$26
Apr-22-22 Resumed Goldman
Buy
$35
Apr-20-22 Initiated Goldman
Buy
$35
Jan-27-22 Upgrade Cantor Fitzgerald
Hold → Overweight
$32
Dec-01-21 Initiated Citigroup
Neutral
$22
Oct-07-21 Upgrade Jefferies
Hold → Buy
$36
Sep-02-21 Downgrade BofA Securities
Neutral → Underperform
$27
Oct-15-20 Upgrade Mizuho
Neutral → Buy
$19 → $24
Jul-30-20 Downgrade Goldman
Neutral → Sell
$19 → $15
Feb-14-20 Reiterated H.C. Wainwright
Neutral
$26 → $25
Feb-14-20 Downgrade JP Morgan
Overweight → Neutral
$21
Feb-14-20 Downgrade BofA/Merrill
Buy → Neutral
$31 → $20
Feb-06-20 Initiated Mizuho
Neutral
Show Previous Ratings
May-03-24 09:00AM
(Investor's Business Daily)
May-02-24 11:39AM
11:15AM
07:00AM
May-01-24 11:54AM
11:07AM
Loading…
11:07AM
09:36AM
09:30AM
08:30AM
07:26AM
(Associated Press Finance)
07:00AM
Apr-30-24 08:00AM
(Investor's Business Daily)
Apr-24-24 07:00AM
Apr-22-24 02:14PM
Apr-17-24 04:00PM
10:01AM
Loading…
10:01AM
Apr-11-24 10:15AM
10:00AM
Apr-10-24 09:45AM
Apr-09-24 12:38PM
(Associated Press Finance)
07:00AM
Apr-08-24 07:00AM
Apr-02-24 12:10PM
Mar-18-24 07:01PM
Mar-15-24 06:15PM
Mar-13-24 12:45PM
Mar-12-24 09:50AM
Mar-10-24 10:00AM
Mar-08-24 09:45AM
Mar-07-24 06:15PM
07:00AM
Loading…
07:00AM
Feb-29-24 06:15PM
Feb-23-24 09:50AM
Feb-21-24 09:45AM
Feb-16-24 10:18AM
Feb-15-24 02:40PM
(Investor's Business Daily) +16.33%
01:34PM
09:30AM
07:37AM
07:30AM
(Associated Press Finance)
07:00AM
Feb-12-24 09:16AM
Feb-08-24 04:10PM
04:00PM
10:00AM
Feb-07-24 06:15PM
Feb-02-24 02:15AM
Feb-01-24 06:15PM
05:00PM
Jan-30-24 12:10PM
Jan-26-24 06:15PM
Jan-15-24 04:51PM
Jan-12-24 06:15PM
Jan-03-24 04:00PM
07:00AM
Dec-27-23 11:45AM
Dec-22-23 06:15PM
Dec-20-23 02:15PM
12:15PM
Dec-18-23 01:45PM
Dec-14-23 10:45AM
06:05AM
Dec-13-23 04:08AM
Dec-11-23 02:30PM
Dec-01-23 06:16PM
Nov-29-23 03:15PM
Nov-24-23 11:31AM
Nov-21-23 04:00PM
11:45AM
Nov-20-23 01:45PM
Nov-16-23 10:30AM
Nov-15-23 08:57AM
07:15AM
07:00AM
Nov-14-23 01:45PM
10:33AM
05:50AM
Nov-13-23 09:50PM
12:45PM
Nov-10-23 03:00PM
Nov-09-23 11:12AM
Nov-08-23 11:30AM
Nov-07-23 04:00PM
Nov-04-23 12:16PM
Oct-31-23 05:08PM
01:30PM
Oct-26-23 12:00PM
10:37AM
Oct-25-23 12:38PM
09:30AM
07:23AM
(Associated Press Finance)
07:00AM
Oct-24-23 09:51AM
Oct-23-23 04:00PM
(Investor's Business Daily) -9.59%
02:00PM
08:00AM
Oct-19-23 10:01AM
Oct-18-23 06:15PM
04:00PM
Oct-16-23 12:30PM
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Nichols Christian Todd SVP, Chief Commercial Officer Mar 18 '24 Sale 28.10 10,417 292,740 65,911 Mar 18 04:02 PM Parisi Samuel Joseph VP, Finance (Interim PAO) Feb 27 '24 Sale 29.65 2,559 75,874 7,717 Feb 27 04:09 PM LAURENCIN CATO T Director Feb 15 '24 Option Exercise 22.52 2,690 60,579 17,859 Feb 16 04:01 PM LAURENCIN CATO T Director Feb 15 '24 Sale 31.85 2,690 85,676 15,169 Feb 16 04:01 PM LAURENCIN CATO T Director Jun 08 '23 Option Exercise 22.97 2,638 60,595 10,117 Jun 08 04:31 PM LAURENCIN CATO T Director Jun 08 '23 Sale 31.85 2,638 84,020 7,479 Jun 08 04:31 PM LAURENCIN CATO T Director Jun 07 '23 Option Exercise 22.97 2,800 64,316 10,279 Jun 07 05:12 PM LAURENCIN CATO T Director Jun 07 '23 Sale 31.50 2,800 88,200 7,479 Jun 07 05:12 PM Nichols Christian Todd SVP, Chief Commercial Officer May 30 '23 Option Exercise 20.43 19,634 401,123 68,118 May 30 08:16 PM Nichols Christian Todd SVP, Chief Commercial Officer May 30 '23 Sale 28.93 27,134 784,862 40,984 May 30 08:16 PM Wysenski Nancy Director May 09 '23 Option Exercise 31.13 41,250 1,284,112 57,079 May 10 04:34 PM Wysenski Nancy Director May 09 '23 Sale 31.24 41,250 1,288,786 15,829 May 10 04:34 PM
Index RUT P/E - EPS (ttm) -2.80 Insider Own 13.65% Shs Outstand 53.68M Perf Week 9.87%
Market Cap 1.23B Forward P/E - EPS next Y -4.10 Insider Trans -0.20% Shs Float 46.39M Perf Month -1.42%
Income -147.03M PEG - EPS next Q -1.16 Inst Own 98.11% Short Float 14.29% Perf Quarter -11.02%
Sales 91.37M P/S 13.48 EPS this Y -73.59% Inst Trans -4.11% Short Ratio 10.58 Perf Half Y -37.49%
Book/sh 10.46 P/B 2.19 EPS next Y 14.39% ROA -20.22% Short Interest 6.63M Perf Year -65.81%
Cash/sh 11.54 P/C 1.99 EPS next 5Y 34.07% ROE -24.85% 52W Range 19.65 - 79.65 Perf YTD -36.90%
Dividend Est. - P/FCF - EPS past 5Y 6.83% ROI -25.70% 52W High -71.21% Beta 0.24
Dividend TTM - Quick Ratio 11.24 Sales past 5Y 4680.14% Gross Margin 77.94% 52W Low 16.69% ATR (14) 1.23
Dividend Ex-Date - Current Ratio 11.24 EPS Y/Y TTM -10.63% Oper. Margin -209.08% RSI (14) 52.53 Volatility 5.47% 5.00%
Employees 173 Debt/Eq 0.02 Sales Y/Y TTM 69.50% Profit Margin -160.91% Recom 1.44 Target Price 68.50
Option/Short Yes / Yes LT Debt/Eq 0.02 EPS Q/Q -1169.13% Payout - Rel Volume 1.04 Prev Close 22.04
Sales Surprise -85.32% EPS Surprise -7.18% Sales Q/Q -99.37% Earnings Feb 15 AMC Avg Volume 626.31K Price 22.93
SMA20 5.71% SMA50 -7.45% SMA200 -40.95% Trades
Volume 653,656 Change 4.04%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-30-24 Downgrade BofA Securities
Buy → Neutral
$68 → $38
Dec-12-23 Initiated Deutsche Bank
Buy
$62
Apr-24-23 Initiated SVB Securities
Outperform
$80
Jan-27-23 Initiated Piper Sandler
Overweight
$94
Nov-04-22 Downgrade RBC Capital Mkts
Outperform → Sector Perform
$52 → $55
Sep-28-22 Upgrade BofA Securities
Neutral → Buy
Nov-19-21 Initiated JMP Securities
Mkt Outperform
$77
Jun-18-21 Upgrade BofA Securities
Underperform → Neutral
$12 → $49
Jun-08-21 Reiterated Oppenheimer
Outperform
$45 → $54
May-26-21 Initiated Citigroup
Buy
$39
Feb-26-21 Upgrade RBC Capital Mkts
Sector Perform → Outperform
$14 → $28
Feb-12-21 Upgrade Jefferies
Hold → Buy
$15 → $30
Feb-02-21 Upgrade BTIG Research
Neutral → Buy
$29
Dec-07-20 Initiated H.C. Wainwright
Buy
$22
Jul-09-20 Upgrade Oppenheimer
Perform → Outperform
$16
Nov-19-19 Upgrade Evercore ISI
In-line → Outperform
$14
May-21-18 Downgrade Barclays
Equal Weight → Underweight
$14 → $12
Apr-23-18 Downgrade Jefferies
Buy → Hold
Apr-05-18 Reiterated Barclays
Overweight
$70 → $50
Nov-20-17 Downgrade Wedbush
Outperform → Neutral
$75 → $55
Show Previous Ratings
May-01-24 04:05PM
Apr-25-24 10:01AM
Apr-15-24 04:05PM
Mar-28-24 08:00AM
(Investor's Business Daily)
Mar-05-24 04:05PM
04:05PM
Loading…
Mar-04-24 04:05PM
Feb-21-24 04:05PM
Feb-16-24 01:33PM
10:33AM
Feb-15-24 04:50PM
(Associated Press Finance)
04:48PM
04:05PM
Feb-08-24 04:05PM
Jan-24-24 11:02PM
Jan-10-24 12:06PM
05:38AM
Loading…
05:38AM
Jan-08-24 08:30AM
Dec-21-23 09:01AM
Dec-17-23 05:41AM
Dec-01-23 11:05AM
Nov-29-23 08:35AM
(Investor's Business Daily)
Nov-20-23 06:00AM
Nov-17-23 01:35PM
08:15AM
(Investor's Business Daily)
Nov-03-23 11:34AM
Nov-02-23 07:03PM
06:25PM
05:24PM
(Associated Press Finance)
04:05PM
Oct-30-23 10:00AM
04:09PM
Loading…
Oct-26-23 04:09PM
(Investor's Business Daily) -14.62%
04:05PM
10:02AM
05:02AM
Oct-18-23 11:20AM
Oct-17-23 07:57AM
Oct-16-23 11:54AM
11:42AM
Oct-12-23 05:01AM
Oct-07-23 03:33PM
Oct-05-23 09:01AM
Sep-28-23 05:01AM
Sep-19-23 09:01PM
Sep-14-23 01:32PM
Sep-07-23 12:00PM
Aug-31-23 04:05PM
Aug-04-23 09:13AM
Aug-03-23 05:55PM
04:49PM
04:05PM
Aug-02-23 07:57AM
Jul-27-23 04:05PM
Jul-18-23 05:36PM
05:36PM
11:30AM
Jul-17-23 08:35AM
Jul-13-23 09:22AM
Jul-11-23 04:05PM
08:59AM
Jul-10-23 04:10PM
Jul-07-23 09:51AM
Jun-27-23 04:05PM
Jun-12-23 09:25AM
Jun-08-23 12:41PM
Jun-02-23 04:05PM
May-16-23 04:05PM
May-10-23 06:13AM
May-05-23 12:27PM
May-04-23 06:45PM
05:39PM
04:05PM
Apr-27-23 04:05PM
10:02AM
Apr-24-23 04:05PM
Apr-18-23 02:34PM
Apr-14-23 07:30AM
Apr-13-23 08:00AM
Apr-06-23 01:49PM
Mar-31-23 09:20AM
Mar-21-23 04:05PM
Mar-14-23 04:05PM
Mar-01-23 05:20AM
Feb-24-23 11:36AM
Feb-23-23 04:05PM
Feb-16-23 04:05PM
Feb-05-23 05:03AM
Feb-03-23 04:05PM
Feb-01-23 10:48AM
Jan-31-23 04:05PM
Jan-15-23 09:01AM
Dec-14-22 10:38PM
Dec-13-22 04:12PM
Dec-12-22 11:30AM
Nov-29-22 12:42PM
Nov-22-22 10:07AM
Nov-21-22 04:05PM
Nov-14-22 02:34PM
Nov-09-22 06:07AM
Nov-07-22 09:11AM
Nov-04-22 11:13AM
Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm's clinical pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Walker Karin L Chief Accounting Officer Jan 24 '24 Option Exercise 13.53 5,000 67,650 5,000 Jan 24 07:01 PM Walker Karin L Chief Accounting Officer Jan 24 '24 Sale 34.00 5,000 170,000 0 Jan 24 07:01 PM Walker Karin L Chief Accounting Officer Dec 20 '23 Option Exercise 13.53 5,000 67,650 5,000 Dec 20 07:17 PM Walker Karin L Chief Accounting Officer Dec 20 '23 Sale 37.19 5,000 185,952 0 Dec 20 07:17 PM Walker Karin L Chief Accounting Officer Nov 30 '23 Option Exercise 13.53 5,000 67,650 5,000 Nov 30 06:24 PM Walker Karin L Chief Accounting Officer Nov 30 '23 Sale 34.00 5,000 170,000 0 Nov 30 06:24 PM Walker Karin L Chief Accounting Officer Oct 25 '23 Option Exercise 13.53 5,000 67,650 5,000 Oct 25 08:03 PM Walker Karin L Chief Accounting Officer Oct 25 '23 Sale 41.04 5,000 205,191 0 Oct 25 08:03 PM Smith Brandon S. Chief Operating Officer Oct 11 '23 Option Exercise 11.12 4,000 44,480 4,000 Oct 11 08:25 PM Smith Brandon S. Chief Operating Officer Oct 11 '23 Sale 46.75 4,000 186,985 0 Oct 11 08:25 PM Karp Carol D. Chief Regulatory Officer Oct 04 '23 Option Exercise 12.15 5,000 60,750 5,000 Oct 04 07:52 PM Karp Carol D. Chief Regulatory Officer Oct 04 '23 Sale 46.62 5,000 233,084 0 Oct 04 07:52 PM Malecek Michael J Chief Legal Officer Sep 27 '23 Option Exercise 10.27 5,000 51,350 5,000 Sep 27 08:35 PM Malecek Michael J Chief Legal Officer Sep 27 '23 Sale 47.38 5,000 236,885 0 Sep 27 08:35 PM Walker Karin L Chief Accounting Officer Sep 19 '23 Option Exercise 15.04 5,000 75,200 5,000 Sep 19 05:37 PM Walker Karin L Chief Accounting Officer Sep 19 '23 Sale 52.36 5,000 261,807 0 Sep 19 05:37 PM Garren Hideki Chief Medical Officer Sep 13 '23 Option Exercise 24.90 2,000 49,800 2,000 Sep 13 07:33 PM Smith Brandon S. Chief Operating Officer Sep 13 '23 Option Exercise 11.12 4,000 44,480 4,000 Sep 13 07:32 PM Smith Brandon S. Chief Operating Officer Sep 13 '23 Sale 55.49 4,000 221,963 0 Sep 13 07:32 PM Garren Hideki Chief Medical Officer Sep 13 '23 Sale 55.48 2,000 110,952 0 Sep 13 07:33 PM Karp Carol D. Chief Regulatory Officer Sep 06 '23 Option Exercise 12.15 5,000 60,750 5,000 Sep 06 07:42 PM Karp Carol D. Chief Regulatory Officer Sep 06 '23 Sale 54.76 5,000 273,804 0 Sep 06 07:42 PM Malecek Michael J Chief Legal Officer Aug 30 '23 Option Exercise 10.27 5,000 51,350 5,000 Aug 30 07:24 PM Malecek Michael J Chief Legal Officer Aug 30 '23 Sale 55.01 5,000 275,066 0 Aug 30 07:24 PM Walker Karin L Chief Accounting Officer Aug 18 '23 Option Exercise 15.04 5,000 75,200 5,000 Aug 18 08:37 PM Walker Karin L Chief Accounting Officer Aug 18 '23 Sale 57.18 5,000 285,922 0 Aug 18 08:37 PM Garren Hideki Chief Medical Officer Aug 16 '23 Option Exercise 24.90 2,000 49,800 2,000 Aug 16 09:15 PM Smith Brandon S. Chief Operating Officer Aug 16 '23 Option Exercise 11.12 4,000 44,480 4,000 Aug 16 09:15 PM Smith Brandon S. Chief Operating Officer Aug 16 '23 Sale 58.71 4,000 234,844 0 Aug 16 09:15 PM Garren Hideki Chief Medical Officer Aug 16 '23 Sale 58.74 2,000 117,480 0 Aug 16 09:15 PM Karp Carol D. Chief Regulatory Officer Aug 02 '23 Option Exercise 12.15 5,000 60,750 5,000 Aug 02 09:00 PM Zago Wagner M. Chief Scientific Officer Aug 02 '23 Option Exercise 12.15 4,000 48,600 4,000 Aug 02 09:00 PM Karp Carol D. Chief Regulatory Officer Aug 02 '23 Sale 67.01 5,000 335,072 0 Aug 02 09:00 PM Zago Wagner M. Chief Scientific Officer Aug 02 '23 Sale 67.05 4,000 268,182 0 Aug 02 09:00 PM Malecek Michael J Chief Legal Officer Jul 26 '23 Option Exercise 10.27 5,000 51,350 5,000 Jul 26 07:45 PM Malecek Michael J Chief Legal Officer Jul 26 '23 Sale 62.33 5,000 311,638 0 Jul 26 07:45 PM Walker Karin L Chief Accounting Officer Jul 19 '23 Option Exercise 15.04 5,000 75,200 5,000 Jul 19 08:50 PM Walker Karin L Chief Accounting Officer Jul 19 '23 Sale 69.19 5,000 345,943 0 Jul 19 08:50 PM Garren Hideki Chief Medical Officer Jul 12 '23 Option Exercise 24.90 2,000 49,800 2,000 Jul 12 08:45 PM Smith Brandon S. Chief Operating Officer Jul 12 '23 Option Exercise 11.12 4,000 44,480 4,000 Jul 12 08:45 PM Smith Brandon S. Chief Operating Officer Jul 12 '23 Sale 67.51 4,000 270,026 0 Jul 12 08:45 PM Garren Hideki Chief Medical Officer Jul 12 '23 Sale 67.51 2,000 135,027 0 Jul 12 08:45 PM Karp Carol D. Chief Regulatory Officer Jul 05 '23 Option Exercise 12.15 5,000 60,750 5,000 Jul 05 09:33 PM Zago Wagner M. Chief Scientific Officer Jul 05 '23 Option Exercise 12.15 4,000 48,600 4,000 Jul 05 09:32 PM Karp Carol D. Chief Regulatory Officer Jul 05 '23 Sale 68.13 5,000 340,636 0 Jul 05 09:33 PM Zago Wagner M. Chief Scientific Officer Jul 05 '23 Sale 68.16 4,000 272,648 0 Jul 05 09:32 PM Selkoe Dennis J. Director Jul 03 '23 Option Exercise 11.33 5,000 56,650 7,845 Jul 03 06:16 PM Selkoe Dennis J. Director Jul 03 '23 Sale 67.43 5,000 337,150 2,845 Jul 03 06:16 PM Malecek Michael J Chief Legal Officer Jun 28 '23 Option Exercise 10.27 5,000 51,350 5,000 Jun 28 08:45 PM Malecek Michael J Chief Legal Officer Jun 28 '23 Sale 69.82 5,000 349,118 0 Jun 28 08:45 PM Garren Hideki Chief Medical Officer Jun 16 '23 Option Exercise 24.90 7,331 182,542 7,331 Jun 16 07:31 PM Garren Hideki Chief Medical Officer Jun 16 '23 Sale 74.00 7,331 542,494 0 Jun 16 07:31 PM Garren Hideki Chief Medical Officer Jun 14 '23 Option Exercise 24.90 4,669 116,258 4,669 Jun 14 09:15 PM Smith Brandon S. Chief Operating Officer Jun 14 '23 Option Exercise 11.12 5,333 59,303 5,333 Jun 14 09:15 PM Smith Brandon S. Chief Operating Officer Jun 14 '23 Sale 73.98 5,333 394,562 0 Jun 14 09:15 PM Garren Hideki Chief Medical Officer Jun 14 '23 Sale 74.22 4,669 346,516 0 Jun 14 09:15 PM Zago Wagner M. Chief Scientific Officer Jun 07 '23 Option Exercise 26.09 19,000 495,750 19,000 Jun 07 09:49 PM Karp Carol D. Chief Regulatory Officer Jun 07 '23 Option Exercise 13.19 20,000 263,700 20,000 Jun 07 09:49 PM Karp Carol D. Chief Regulatory Officer Jun 07 '23 Sale 71.05 20,000 1,421,009 0 Jun 07 09:49 PM Zago Wagner M. Chief Scientific Officer Jun 07 '23 Sale 71.06 19,000 1,350,224 0 Jun 07 09:49 PM Malecek Michael J Chief Legal Officer May 31 '23 Option Exercise 10.27 5,000 51,350 5,000 May 31 09:30 PM Malecek Michael J Chief Legal Officer May 31 '23 Sale 64.64 5,000 323,223 0 May 31 09:30 PM Walker Karin L Chief Accounting Officer May 19 '23 Option Exercise 15.04 5,000 75,200 5,000 May 19 09:31 PM Walker Karin L Chief Accounting Officer May 19 '23 Sale 74.00 5,000 369,978 0 May 19 09:31 PM Nguyen Tran Chief Strategy Officer and CFO May 17 '23 Option Exercise 26.15 95,000 2,483,950 98,200 May 17 09:53 PM Kinney Gene G. President and CEO May 17 '23 Option Exercise 29.81 45,000 1,341,450 57,793 May 17 09:54 PM Nguyen Tran Chief Strategy Officer and CFO May 17 '23 Sale 73.99 95,000 7,028,921 3,200 May 17 09:53 PM Kinney Gene G. President and CEO May 17 '23 Sale 73.70 45,000 3,316,292 12,793 May 17 09:54 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
